M&A Deal Summary

Acino Acquires IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements

On April 1, 2021, Acino acquired life science company IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements from Ilmix Group

Acquisition Highlights
  • This is Acino’s 3rd transaction in the Life Science sector.
  • This is Acino’s 1st transaction in Russia.

M&A Deal Summary
Date 2021-04-01
Target IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements
Sector Life Science
Buyer(s) Acino
Sellers(s) Ilmix Group
Deal Type Divestiture

Target

IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements

Saint Petersburg, Russia
IlmixGroup's Select Portfolio of Prescription Pharmaceutical Products and Food Supplements includes eight prescription pharmaceutical assets and food supplements in the areas of gynecology, gynecologic oncology, urology, and dermatology. The portfolio includes Indinol Forto, Cervicon-DIM, Indinol, Epigallate, Promisan, Indigal, and other clinical assets that are currently under development. These products are mainly used for the prevention and treatment of endometriosis, myoma, cervical dysplasia and prostate adenoma, and other disorders affecting the human reproductive system.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Acino

Zurich, Czech Republic
Category Company
Founded 1836
Sector Life Science
Employees2,400
DESCRIPTION

Acino is a pharmaceutical company focused on developing, manufacturing and marketing well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino was founded in 1836 and is based in Zurich, Czech Republic.

DEAL STATS #
Overall 5 of 7
Sector (Life Science) 3 of 4
Type (Divestiture) 4 of 5
Country (Russia) 1 of 1
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-15 Takeda Pharmaceutical - Primary Care Portfolio

Osaka, Japan

Takeda’s primary care portfolio includes pain management, gastroenterology, cardiovascular and respiratory and other 30 products.

Buy $200M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-01 Aspen Pharmacare Holdings - Prescription Medicines

Durban, South Africa

Aspen brands portfolio includes the Trustan, Altosec, Zuvamor, Ciavor, Grantryl, and Aspen Granisetron brands.

Buy €105M

Seller(S) 1

SELLER

Ilmix Group

Saint Petersburg, Russia
Category Company
Founded 2003
Sector Life Science
DESCRIPTION

Ilmix Group is a pharmaceutical full-cycle company focused on world quality standards and unique competencies in the field of scientific research, development, production, and promotion of innovative drugs. The company is active in the commercial segment of non-hormonal drugs for women’s and men’s reproductive health and cancer prevention, with a primary specialization in the therapy of benign breast diseases and cervical dysplasia. Ilmix Group was founded in 2003 and is based in Saint Petersburg, 191025, Russia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Russia) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal